Global Active Pharmaceutical Ingredients (API) Market to Reach $265.3 Billion by 2026

SAN FRANCISCO, March 3, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Active Pharmaceutical Ingredients (API) - Global Market Trajectory & Analytics". The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.

FACTS AT A GLANCE

What's New for 2022?

• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to our digital archives and MarketGlass Research Platform
• Complimentary updates for one year

Edition: 8; Released: February 2022
Executive Pool: 5211
Companies: 266 - Players covered include AbbVie, Inc.; AstraZeneca PLC; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche AG; GlaxoSmithKline PLC; Pfizer, Inc.; Sanofi; Teva Pharmaceutical Industries Ltd. and Others.
Coverage: All major geographies and key segments
Segments: Type (Innovative, Generic); Synthesis (Synthetic, Biotech); Application (Cardiovascular Diseases, Endocrinology, CNS & Neurology, Oncology, Gastroenterology, Orthopedic, Other Applications)
Geographies: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Complimentary Project Preview - This is an ongoing global program. Preview our research program before you make a purchase decision. We are offering a complimentary access to qualified executives driving strategy, business development, sales & marketing, and product management roles at featured companies. Previews provide deep insider access to business trends; competitive brands; domain expert profiles; and market data templates and much more. You may also build your own bespoke report using our MarketGlass™ Platform which offers thousands of data bytes without an obligation to purchase our report. Preview Registry

ABSTRACT-

Global Active Pharmaceutical Ingredients (API) Market to Reach US$265.3  Billion by the Year 2026
APIs represent biologically-active substances and primary components for drug manufacturing. The production of APIs globally is mainly concentrated to developing nations due to their capability to scale production as per customization and low-cost manufacturing. The API market is slated to gain from increasing focus on generic and branded drugs as a result of rising prevalence of non-communicable and chronic medical conditions due to lifestyle changes and rapid urbanization. The market growth is anticipated to be augmented further from the transition away from conventional manufacturing techniques, rising investment in drug discovery, and strong adherence to product quality. The market is also benefitting from increasing influx of generic drugs that are produced following permission of a pharmaceutical company for creating the own version of the medicine. The COVID-19 pandemic and the resulting disruptions in supply chain are driving various governments to boycott sourcing of APIs from China. Despite these challenges, the API market is bound to progress ahead swiftly due to positive factors like pending approval of various generic and blockbuster drugs that rely on APIs.

Amid the COVID-19 crisis, the global market for Active Pharmaceutical Ingredients (API) estimated at US$213.2 Billion in the year 2022, is projected to reach a revised size of US$265.3 Billion by 2026, growing at a CAGR of 6.7% over the analysis period. Innovative, one of the segments analyzed in the report, is projected to grow at a 6.4% CAGR to reach US$190.9 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Generic segment is readjusted to a revised 7.4% CAGR for the next 7-year period. This segment currently accounts for a 30.2% share of the global Active Pharmaceutical Ingredients (API) market. As patents for branded APIs expire, opportunities for generic APIs increase, resulting in an augmented API market demand.

The U.S. Market is Estimated at $77.1 Billion in 2022, While China is Forecast to Reach $35.4 Billion by 2026
The Active Pharmaceutical Ingredients (API) market in the U.S. is estimated at US$77.1 Billion in the year 2022. The country currently accounts for a 36.3% share in the global market. China, the world's second largest economy, is forecast to reach an estimated market size of US$35.4 Billion in the year 2026 trailing a CAGR of 7.6% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.1% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR while Rest of European market (as defined in the study) will reach US$37.5 Billion by the end of the analysis period. China is a leading producer and exporter of APIs, accounting for about 20% of global API production. The country's strong presence in API production could be attributed to factors such as low cost of utilities and strong government support. COVID-19 has highlighted various vulnerabilities associated with sourcing of APIs from other regions or countries, such as fractured supply chain and limited scope for immediate response to changes. These challenges are now prompting a number of European nations and the US to focus on relocation of pharmaceutical and API production back to home country.

Personalized Medicine Spurs Demand for Complex API
Known alternatively by the terms targeted medicine or precision medicine, the personalized medicine science involves precision diagnosis of patients through non-invasive sample collection and analysis for better stratification of diseases using genetic and other markers and subsequent selection of drugs for treatment that suits to the individual based on personal information secured. While the idea has of personal medicine is not totally new given that doctors use patient profiles, environmental factors and diagnostic information to determine the most appropriate treatment, what defines the modern day personalized medicine is the technological advancements that provide genetic level information of patients never before available for the doctors. Improved molecular and genetic tests are enabling doctors to understand DNA and RNA level variations in patients with same diseases, enabling them to choose therapies that target these variations to affect a desirable outcome.

Active pharmaceutical ingredients (APIs) developed for personalized drug products are more complex and require specialized handling. Personalized 3D printing drugs facilitate personalized drug dosing, novel drug release profile and distinct dosage form production. Active pharmaceutical ingredients are compounded in a polymer matrix in pharmaceutical hot melt extrusion (HME).

Today, personalized medicine is a key area of research within the healthcare industry. Having become an integral part of mainstream clinical practice, personalized medicine is transforming the way a large number of diseases are identified, categorized, and treated. At present, over 150 personalized medicines are on the market. Furthermore, some 40% of drugs under development target biomarkers. Over the past five years, investments in personalized medicines have doubled and are expected to clock significant growth in the foreseeable future. Oncology is presently the largest therapeutic category in personalized medicines. The unmet need and potential in this space can be further assessed by the fact that three-fourth of the cancer drugs under development are personalized medicines. More

MarketGlass™ Platform
Our MarketGlass™ Platform is a free full-stack knowledge center that is custom configurable to today`s busy business executive`s intelligence needs! This influencer driven interactive research platform is at the core of our primary research engagements and draws from unique perspectives of participating executives worldwide. Features include - enterprise-wide peer-to-peer collaborations; research program previews relevant to your company; 3.4 million domain expert profiles; competitive company profiles; interactive research modules; bespoke report generation; monitor market trends; competitive brands; create & publish blogs & podcasts using our primary and secondary content; track domain events worldwide; and much more. Client companies will have complete insider access to the project data stacks. Currently in use by 67,000+ domain experts worldwide.

Our platform is free for qualified executives and is accessible from our website www.StrategyR.com or via our just released mobile application on iOS or Android

About Global Industry Analysts, Inc. & StrategyR™
Global Industry Analysts, Inc., (www.strategyr.com) is a renowned market research publisher the world`s only influencer driven market research company. Proudly serving more than 42,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for over 33 years.

CONTACTS:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
www.StrategyR.com
Email: [email protected]

LINKS
Join Our Expert Panel
https://www.strategyr.com/Panelist.asp

Connect With Us on LinkedIn
https://www.linkedin.com/company/global-industry-analysts-inc./

Follow Us on Twitter
https://twitter.com/marketbytes

Journalists & Media
[email protected]

SOURCE Global Industry Analysts, Inc.